# OnCo record zeprumetostat (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/zeprumetostat/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "zeprumetostat" ;
  schema:name "Zeprumetostat"@en ;
  schema:alternateName "TLN-254"@en, "SHR2554"@en, "Airuijing"@en ;
  schema:description "Zeprumetostat is a tablet that blocks EZH2, an enzyme that switches genes off; China approved it in 2025 for peripheral T-cell lymphoma that came back after treatment, and Treeline Biosciences is testing it in phase 1 elsewhere."@en ;
  schema:url <https://onco.cc/drugs/zeprumetostat/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://treeline.bio/medicines>, <https://treeline.bio/medicines>, <https://doi.org/10.1007/s40265-025-02271-0>, <https://clinicaltrials.gov/search?intr=TLN-254> ;
  onco:status "approved" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Small molecule EZH2 inhibitor" ;
  onco:approval "China 2025: Relapsed or refractory peripheral T-cell lymphoma after at least one line of systemic therapy (conditional approval)" ;
  onco:cancers <https://onco.cc/cancers/peripheral-t-cell-lymphoma/>, <https://onco.cc/cancers/cutaneous-t-cell-lymphoma/> ;
  onco:targets <https://onco.cc/targets/ezh2/> ;
  onco:companies <https://onco.cc/companies/treeline-biosciences/>, <https://onco.cc/companies/hengrui/> ;
  onco:trials <https://onco.cc/trials/nct06733441/>, <https://onco.cc/trials/nct07082803/>, <https://onco.cc/trials/nct07230106/>, <https://onco.cc/trials/nct07175220/>, <https://onco.cc/trials/nct07102901/>, <https://onco.cc/trials/nct06679673/> .